Department of Medicine, Margaret Corbin Campus of the VA New York Harbor Health Care System, New York, NY, USA; Laboratory of Translational Obesity Research, NYU Langone Health, New York, NY, USA.
Department of Medicine, Margaret Corbin Campus of the VA New York Harbor Health Care System, New York, NY, USA; Laboratory of Translational Obesity Research, NYU Langone Health, New York, NY, USA; Holman Division of Endocrinology, New York University Langone Health, 423 East 23rd Street, Room 16-048W, New York, NY 10010, USA.
Gastrointest Endosc Clin N Am. 2024 Oct;34(4):591-608. doi: 10.1016/j.giec.2024.06.006.
The rising prevalence of obesity is of major concern. There are currently 5 Food and Drug Administration-approved medications for the treatment of obesity: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide 3.0 mg, and semaglutide 2.4 mg. Surgical options such as bariatric surgery and endoscopic surgery induce more durable weight loss than pharmacotherapy or lifestyle interventions alone. However, patients often experience weight regain and weight loss plateau after surgery. The addition of multimodal or multihormonal pharmacotherapy is a promising tool to address these challenges. The optimal timing of obesity pharmacotherapy with surgical and endoscopic interventions requires further investigation.
肥胖症的患病率不断上升,令人尤为担忧。目前有 5 种经美国食品药品监督管理局批准的肥胖症治疗药物:奥利司他、苯丁胺/托吡酯、纳曲酮/安非他酮、利拉鲁肽 3.0mg 和司美格鲁肽 2.4mg。与单独药物治疗或生活方式干预相比,减重手术和内镜手术等手术选择可诱导更持久的体重减轻。然而,患者在手术后常常会经历体重反弹和体重减轻平台期。多模式或多激素药物治疗的联合应用是解决这些挑战的一种有前途的手段。肥胖症药物治疗与手术和内镜干预的最佳时机仍需要进一步研究。